Thiadiazolo‐Triazolo‐Pyrimidine Hybrids as Dual Aurora A/ERK Inhibitors: Design, Synthesis, and Apoptotic Activity
Drug Development Research · 2026
DOI: 10.1002/ddr.70364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Mai A E Mourad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry Department, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt. Hauptthemen laut MEDLINE: Aurora Kinase A, Pyrimidines, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aberrant activation of Aurora A kinase causes mitotic spindle assembly, chromosome segregation, and cell cycle progression, leading to genomic instability as well as disruption of several tumor suppressors. Furthermore, ERK has largely emerged as a survival signaling pathway controlling cell proliferation, differentiation, and metastasis. Unfortunately, this pathway is overexpressed in most of the human malignancies. In efforts to develop innovative inhibitors targeting Aurora A/ERK signaling pathway, a novel series of thiadiazolo‐, triazolo‐pyrimidine hybrids have been designed, synthesized, and assessed for their ability to block Aurora A/ERK and induce apoptosis. Cytotoxicity of the synthesized hybrids was examined against MCF‐7, HCT‐116 and A549 cell lines. Among the synthesized hybrids, 9a , 9c , and 14b demonstrated higher cytotoxic action than alisertib and GDC‐0994 against the MCF‐7 and A549 cancer cell lines. IC 50 values for these hybrids were 2.59 ± 0.13, 4.63 ± 0.25, and 5.77 ± 0.38, respectively, against MCF‐7 cell line and were 3.61 ± 0.19, 3.85 ± 0.21, and 4.23 ± 0.15, respectively, against A549. The selected hybrids significantly suppressed p‐Aurora A kinase level as well as p‐ERK1/2 level and its upstream regulators p‐SRC, p‐c‐RAF, p‐MEK1/2; meanwhile, ERK downstream effectors FOXO3a level was upregulated, and c‐Myc was downregulated, in a dose‐dependent manner. The selected hybrids significantly decreased the expression of Bcl‐2 protein while increasing the levels of p53 , caspase‐7, caspase‐9, and Bax. They effectively induced pre‐G1 phase, G0/G1 phase apoptosis, and G2/M phase arrest. The synthesized hybrids possessed favorable binding interactions in the molecular docking investigations as well as appropriate drug‐like characteristics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicinal Chemistry Department, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt.
- Medicinal Chemistry Department, Faculty of Pharmacy, East Port-Said National University, Port-Said, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Qena University, Qena, Egypt.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, East Port-Said National University, Port-Said, Egypt.
ORCID-Profile: Mai A E Mourad, Amal Hofni, Ahmed A E Mourad
Zitieren
APA
Mourad, M. A. E., Hofni, A., & Mourad, A. A. E. (2026). Thiadiazolo‐Triazolo‐Pyrimidine Hybrids as Dual Aurora A/ERK Inhibitors: Design, Synthesis, and Apoptotic Activity. Drug Development Research. https://doi.org/10.1002/ddr.70364
Vancouver
Mourad MAE, Hofni A, Mourad AAE. Thiadiazolo‐Triazolo‐Pyrimidine Hybrids as Dual Aurora A/ERK Inhibitors: Design, Synthesis, and Apoptotic Activity. Drug Development Research. 2026. doi:10.1002/ddr.70364
BibTeX
@article{Mourad2026,
author = {Mourad, Mai A E and Hofni, Amal and Mourad, Ahmed A E},
title = {Thiadiazolo‐Triazolo‐Pyrimidine Hybrids as Dual Aurora A/ERK Inhibitors: Design, Synthesis, and Apoptotic Activity},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70364}
}
EUVIMED